Gain Therapeutics Schedules Parkinson's Data Presentation
Question
Gain Therapeutics Schedules Parkinson's Data Presentation
Direct answer
Gain Therapeutics (GANX) has scheduled a poster presentation detailing long-term open-label data for its lead drug candidate rexaceract (GT-02287) at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, Korea on October 7, 2026. GT-02287 targets glucocerebrosidase (GCase) enzyme modulation, representing a novel mechanism for slowing Parkinson's disease progression, making the upcoming clinical readout a pivotal valuation catalyst.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-30
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Gain Therapeutics Schedules Parkinson's Data Presentation”, revision 1, evidence through 2026-09-30. https://marketontology.com/market-events/2026-09-30/gain-therapeutics-schedules-parkinson-s-data-presentation-a2f252
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| GANX | clinical pipeline milestone and trial efficacy readout | Up1-4w | Poster presentation of long-term open-label data on GT-02287 scheduled for October 7, 2026. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.